Neutralizing antibodies and methods of use thereof
AssigneeNovImmune S.A.
InventorsGreg Elson, Olivier Leger
Life of this patent
Estimating the term…
Abstract
This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.
Claims4
A humanized antibody that immunospecifically binds to a Toll-like receptor 4 (TLR4)/MD-2 complex, wherein the antibody comprises the heavy chain variable amino acid sequence of SEQ ID NO:
- 51 and the light chain variable amino acid sequence of SEQ ID NO:
- 53.
A humanized antibody that immunospecifically binds to a Toll-like receptor 4 (TLR4)/MD-2 complex, wherein the antibody comprises a heavy chain with three complementarity determining regions (CDRs) comprising a variable heavy chain CDR1 region (VH CDR1) comprising the amino acid sequence TYNIGVG (SEQ ID NO:97), a variable heavy chain CDR2 region (VH CDR2) comprising the amino acid sequence HIWWNDNIYYNTVLKS (SEQ ID NO:98), a variable heavy chain CDR3 region (VH CDR3) comprising the amino acid sequence MAEGRYDAMDY (SEQ ID NO:99), a variable light chain CDR1 region (VL CDR1) comprising the amino acid sequence RASQDITNYLN (SEQ ID NO:100), a variable light chain CDR2 region (VL CDR2) comprising the amino acid sequence YTSKLHS (SEQ ID NO:101), and a variable light chain CDR3 region (VL CDR3) comprising the amino acid sequence QQGNTFPWT (SEQ ID NO:102).
Dependencies are inferred from the claim text.